<DOC>
	<DOCNO>NCT01696435</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ; NCT 01169259 ) ongoing randomize clinical trial 25,875 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( OmacorÂ® fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among participant VITAL examine whether vitamin D fish oil : 1 ) reduces risk clinical depressive syndrome , 2 ) yield well mood score time , compare placebo .</brief_summary>
	<brief_title>VITAL-DEP : Depression Endpoint Prevention VITamin D OmegA-3 TriaL</brief_title>
	<detailed_description>VITAL-DEP : Depression Endpoint Prevention VITamin D OmegA-3 TriaL randomize clinical trial vitamin D ( form vitamin D3 [ cholecalciferol ] ) marine omega-3 fatty acid ( eicosapentaenoic acid [ EPA ] + docosahexaenoic acid [ DHA ] ) supplement prevention depression old adult . Existing data laboratory study , epidemiologic research , limited clinical trial research suggest nutritional agent may reduce risk depression improve mood , large primary prevention trial adequate dose lengthy treatment duration general population lack . Eligible participant assign chance ( like coin toss ) one four group : ( 1 ) daily vitamin D3 omega-3 ; ( 2 ) daily vitamin D3 omega-3 placebo ; ( 3 ) daily vitamin D placebo omega-3 ; ( 4 ) daily vitamin D placebo omega-3 placebo . Participants equal chance assign four group 3 4 chance get least one active agent . Participants group take two pill day -- one softgel contain either vitamin D3 vitamin D placebo one capsule contain either omega-3 omega-3 placebo . Participants receive study pill convenient calendar package via U.S. mail . Participants also fill short ( 15-20 minute ) questionnaire year . The questionnaire ask health ; lifestyle habit physical exercise , diet , smoking ; use medication dietary supplement ; family history illness , new medical diagnosis . The questionnaire also include specific question pertain mood . Occasionally , participant may receive phone call study staff collect information clarify responses questionnaire . Primary aim 1 ) reduction risk clinical depressive syndrome 2 ) yielding well mood score time address full VITAL cohort 20,000 . Secondary aim address sub-set participant . The secondary aim address whether : 1 ) among subset 1,000 participant evaluate Clinical Translational Science Center ( CTSC ) , agent reduce risk depression yield well mood score among person know risk factor late-life depression ; 2 ) among subset 1,000 participant evaluate CTSC , agent reduce risk major depression yield well mood score among person sub-syndromal depressive symptom ; 3 ) among VITAL participant , African-American race ( African-Americans high risk Vitamin D deficiency ) modify effect vitamin D3 supplementation late-life depression risk mood score ; 4 ) among subset participant , baseline plasma level vitamin D omega-3 fatty acid relate depression risk and/or modify agent effect . Thus , VITAL-DEP address simultaneously impact vitamin D fish oil universal , selective indicated prevention late-life depression .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Participants VITAL ( NCT 01169259 ) meet follow criterion eligible participate ancillary study . These criterion specific test primary aim VITALDEP ancillary study : current significant depressive symptom core major depressive disorder symptom period two week past two year history alcohol and/or substance abuse disorder active past 12 month , schizophrenia primary psychotic disorder , bipolar disorder , posttraumatic stress disorder obsessivecompulsive disorder psychiatric hospitalization past 2 year current psychotherapy current use psychotropics ( include nonprescription agent treatment mood disorder ) , except limit use mild sedatives/hypnotics history major neurologic disorder delirium episode past 12 month history clinical ( i.e. , overt subclinical ) hypothyroidism diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Depression</keyword>
	<keyword>Depressive Symptoms</keyword>
	<keyword>Mood</keyword>
	<keyword>Geriatric</keyword>
	<keyword>Prevention</keyword>
</DOC>